Is the price fair?
What CORT's price assumes
Corcept Therapeutics Incorporated trades at 342× earnings against 32.4× for the median Biotechnology name, more expensive than its own group.
342
Trailing P/E · Biotechnology median 32.4 · 10.6× the median: the market pays up for this one
- Price / sales
- 5.47
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.4%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +23%
Growth the price implies · The price pays for +23% free cash flow growth a year for a decade; the business has delivered +2.8% a year over the last three.
Details›
- Price / book2026-Q1
- 6.60
- EV / EBIToperating margin −1.1%: the multiple describes the denominator
- not meaningful
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $120M
- Market capitalisation
- $8.58B
- 3-year revenue growth
- +23%
- 3-year free cash flow growth
- +2.8%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 79.7× today against a 26.9× median |
| 52-week range | $32.15 – $123.53 |
| Today | $119.82 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.